Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Autosomal dominant hypercholesterolemia (ADH; OMIM144400), a risk factor for coronary heart disease, is characterized by an increase in low-density lipoprotein cholesterol levels that is associated with mutations in the genes LDLR (encoding low-density lipoprotein receptor) or APOB (encoding apolipoprotein B). We mapped a third locus associated with ADH, HCHOLA3 at 1p32, and now report two mutations in the gene PCSK9 (encoding proprotein convertase subtilisin/kexin type 9) that cause ADH. PCSK9 encodes NARC-1 (neural apoptosis regulated convertase), a newly identified human subtilase that is highly expressed in the liver and contributes to cholesterol homeostasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mutations conveying gain or loss of function of PCSK9 result in a higher or lower level of LDL cholesterol, respectively, which in turn is associated with a corresponding higher 7 or lower 6 risk of incident coronary heart disease.”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [7]
In the citing paper
“In 2003, Abifadel and colleagues identified gain-of-function mutations in the PCSK9 gene causative of familial hypercholesterolemia, an autosomal dominant trait characterized by an elevation in circulating low-density lipoprotein cholesterol (LDL-C) and premature coronary heart disease (CHD) risk (2).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [2]
In the citing paper
“Autosomal Dominant Hypercholesterolemia (ADH), due to mutations in the LDLR, APOB or PCSK9 genes, is characterized by an isolated elevation of cholesterol due to high levels of low-density lipoproteins (LDL).”
From Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation (2013) · cites this paper as Abifadel M et al. 2003
In the citing paper
“ADH is genetically heterogeneous and associated with mutations in the well-known LDLR (low density lipoprotein receptor) (FH, OMIM #606945), APOB (apolipoprotein B-100) (FDB, OMIM # 144010) and PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9, Abifadel M et al. 2003) genes.”
From Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation (2013) · cites this paper as Abifadel M et al. 2003
In the citing paper
“Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the subtilisin family of proprotein convertases (PCs) [2], with an established role in the systemic control of blood cholesterol and a lesser-characterized role in neuronal development and apoptosis [3,4].”
From PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling (2012) · cites this paper as [3]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
RGD AND OTHER RECOGNITION SEQUENCES FOR INTEGRINS
Ruoslahti, E. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.697 · Cited by 3,191
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Self-citationA proteolytic pathway that controls the cholesterol content of membranes, cells, and blood
Brown, M. S., & Goldstein, J. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11041 · Cited by 1,134
A Third Major Locus for Autosomal Dominant Hypercholesterolemia Maps to 1p34.1-p32
Varret, M., Rabès, J.-P., Saint-Jore, B., Cenarro, A., Marinoni, J.-C., Civeira, F., Devillers, M., Krempf, M., Coulon, M., Thiart, R., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302370 · Cited by 175
Self-citationBiosynthesis and Cellular Trafficking of the Convertase SKI-1/S1P
Elagoz, A., Benjannet, S., Mammarbassi, A., Wickham, L., & Seidah, N. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109011200 · Cited by 113
Self-citationHunt, S. C., Hopkins, P. N., Bulka, K., McDermott, M. T., Thorne, T. L., Wardell, B. B., Bowen, B. R., Ballinger, D. G., Skolnick, M. H., & Samuels, M. E. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.4.1089 · Cited by 109
Cited by
Items 401–500 of 1,044
PCSK9 and LDL cholesterol: unravelling the target to design the bullet
Costet, P., Krempf, M., & Cariou, B. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.06.005 · Cited by 102
Self-citationFamilial Hypercholesterolemia, Peripheral Arterial Disease, and Stroke: A HuGE Minireview
Hutter, C. M., Austin, M. A., & Humphries, S. E. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh238 · Cited by 102
Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
Punch, E., Klein, J., Diaba‐Nuhoho, P., Morawietz, H., & Garelnabi, M. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023328 · Cited by 101
Duan, Y., Chen, Y., Hu, W., Li, X., Yang, X., Zhou, X., Yin, Z., Kong, D., Yao, Z., Hajjar, D. P., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.350181 · Cited by 87
Graham, C. A., McIlhatton, B. P., Kirk, C. W., Beattie, E. D., Lyttle, K., Hart, P., Neely, R. D. G., Young, I. S., & Nicholls, D. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.02.016 · Cited by 101
Motazacker, M. M., Pirruccello, J., Huijgen, R., Do, R., Gabriel, S., Peter, J., Kuivenhoven, J. A., Defesche, J. C., Kastelein, J. J. P., Hovingh, G. K., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs010 · Cited by 89
Experimental and clinical pharmacology: PCSK9 inhibitors - mechanisms of action
Page, M. M., & Watts, G. F. (2016) · Australian Prescriber · doi:10.18773/austprescr.2016.060 · Cited by 101
The Montreal-FH-SCORE: A new score to predict cardiovascular events in familial hypercholesterolemia
Paquette, M., Dufour, R., & Baass, A. W. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.10.004 · Cited by 101
Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease
Glerup, S., Schulz, R., Laufs, U., & Schlüter, K.-D. (2017) · Basic Research in Cardiology · doi:10.1007/s00395-017-0619-0 · Cited by 93
Hypercholesterolemia: The role of PCSK9
Melendez, Q. M., Krishnaji, S. T., Wooten, C. J., & Lopez, D. (2017) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2017.06.001 · Cited by 101
Huang, C.-C., Fornage, M., Lloyd-Jones, D. M., Wei, G. S., Boerwinkle, E., & Liu, K. (2009) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.108.828467 · Cited by 92
Abifadel, M., Rabès, J.-P., Jambart, S., Halaby, G., Gannagé-Yared, M.-H., Sarkis, A., Beaino, G., Varret, M., Salem, N., Corbani, S., et al. (2009) · Human Mutation · doi:10.1002/humu.21002 · Cited by 99
Self-citationDuff, C. J., Scott, M. J., Kirby, I. T., Hutchinson, S. E., Martin, S. L., & Hooper, N. M. (2009) · Biochemical Journal · doi:10.1042/bj20082407 · Cited by 99
Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias
Katzmann, J. L., Packard, C. J., Chapman, M. J., Katzmann, I., & Laufs, U. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.070 · Cited by 99
Genetics, Clinical Phenotype, and Molecular Cell Biology of Autosomal Recessive Hypercholesterolemia
Soutar, A. K., Naoumova, R. P., & Traub, L. M. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000094410.66558.9a · Cited by 99
Karagiannis, A. D., Liu, M., Toth, P. P., Zhao, S., Agrawal, D. K., Libby, P., & Chatzizisis, Y. S. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0718-x · Cited by 99
Protease propeptide structures, mechanisms of activation, and functions
Boon, L., Ugarte-Berzal, E., Vandooren, J., & Opdenakker, G. (2020) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2020.1742090 · Cited by 99
PCSK9 and atherosclerosis: Looking beyond LDL regulation
Ragusa, R., Basta, G., Neglia, D., De Caterina, R., Del Turco, S., & Caselli, C. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13459 · Cited by 90
Using human genetics to improve safety assessment of therapeutics
Carss, K., Deaton, A. M., Río-Espínola, A. D., Diogo, D., Fielden, M. R., Kulkarni, D. A., Moggs, J. G., Newham, P., Nelson, M. R., Sistare, F. D., et al. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00561-w · Cited by 100
I Diretriz Brasileira de Hipercolesterolemia Familiar (HF)
Santos, R., Gagliardi, A., Xavier, H. T., Filho, A. C., Araújo, D., Cesena, F., Alves, R., Pereira, A., Lotemberg, A., Chacra, A., et al. (2012) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20120202 · Cited by 99
Fellin, R., Arca, M., Zuliani, G., Calandra, S., & Bertolini, S. (2014) · Gene · doi:10.1016/j.gene.2014.09.020 · Cited by 99
PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
Liu, M., Wu, G., Baysarowich, J., Kavana, M., Addona, G. H., Bierilo, K. K., Mudgett, J. S., Pavlovic, G., Sitlani, A., Renger, J. J., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m006635 · Cited by 98
Cord blood lipoproteins and prenatal influences
Bansal, N., Cruickshank, J. K., McElduff, P., & Durrington, P. N. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000174154.61307.16 · Cited by 98
Cholesterol in LDL receptor recycling and degradation
Yang, H.-X., Zhang, M., Long, S.-Y., Tuo, Q.-H., Tian, Y., Chen, J.-X., Zhang, C.-P., & Liao, D.-F. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.09.022 · Cited by 98
PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future
Shimada, Y. J., & Cannon, C. P. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv174 · Cited by 98
Proprotein Covertases Are Responsible for Proteolysis and Inactivation of Endothelial Lipase
Jin, W., Fuki, I. V., Seidah, N. G., Benjannet, S., Glick, J. M., & Rader, D. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502264200 · Cited by 98
Self-citationFamilial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management
Najam, O., & Ray, K. K. (2015) · Cardiology and Therapy · doi:10.1007/s40119-015-0037-z · Cited by 98
Emerging Therapeutic Potential of SIRT6 Modulators
Fiorentino, F., Mai, A., & Rotili, D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00601 · Cited by 98
Calandra, S., Tarugi, P., Speedy, H. E., Dean, A. F., Bertolini, S., & Shoulders, C. C. (2011) · Journal of Lipid Research · doi:10.1194/jlr.r017855 · Cited by 87
Retterstøl, K., Svendsen, M., Narverud, I., & Holven, K. B. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.10.013 · Cited by 97
Clinical Interpretation and Management of Genetic Variants
Marian, A. J. (2020) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.05.013 · Cited by 97
FXR an emerging therapeutic target for the treatment of atherosclerosis
Mencarelli, A., & Fiorucci, S. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00997.x · Cited by 91
The cargo receptor SURF4 promotes the efficient cellular secretion of PCSK9
Emmer, B. T., Hesketh, G. G., Kotnik, E., Tang, V. T., Lascuna, P. J., Xiang, J., Gingras, A.-C., Chen, X.-W., & Ginsburg, D. (2018) · eLife · doi:10.7554/elife.38839 · Cited by 96
Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications
Bhattacharjee, G., Gohil, N., Khambhati, K., Mani, I., Maurya, R., Karapurkar, J. K., Gohil, J., Chu, D., Vu‐Thi, H., Alzahrani, K. J., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.005 · Cited by 96
Li, S., Zhang, Y., Xu, R.-X., Guo, Y.-L., Zhu, C.-G., Wu, N.-Q., Qing, P., Liu, G., Dong, Q., & Li, J.-J. (2015) · Annals of Medicine · doi:10.3109/07853890.2015.1042908 · Cited by 90
Miyake, Y., Kimura, R., Kokubo, Y., Okayama, A., Tomoike, H., Yamamura, T., & Miyata, T. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.12.035 · Cited by 96
PCSK9 and Atherosclerosis - Lipids and Beyond
Shapiro, M. D., & Fazio, S. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17003 · Cited by 83
Emdin, C. A., Khera, A. V., Chaffin, M., Klarin, D., Natarajan, P., Aragam, K., Haas, M., Bick, A., Zekavat, S. M., Nomura, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03911-8 · Cited by 95
Loss- and Gain-of-function PCSK9 Variants
Benjannet, S., Hamelin, J., Chrétien, M., & Seidah, N. G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.399725 · Cited by 83
Self-citationHuman Genetics of Obesity and Type 2 Diabetes Mellitus: Past, Present, and Future
Ingelsson, E., & McCarthy, M. I. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.118.002090 · Cited by 81
Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies
Seidah, N. G., Prat, A., Pirillo, A., Catapano, A. L., & Norata, G. D. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz003 · Cited by 87
Self-citationNaturally Occurring PCSK9 Inhibitors
Adorni, M. P., Zimetti, F., Lupo, M. G., Ruscica, M., & Ferri, N. (2020) · Nutrients · doi:10.3390/nu12051440 · Cited by 92
Shen, C., Zhang, R., Yu, J., Sahakian, B. J., Cheng, W., & Feng, J. (2025) · Nature Human Behaviour · doi:10.1038/s41562-024-02078-1 · Cited by 94
Costet, P., Hoffmann, M. M., Cariou, B., Guyomarch, B., Konrad, T., & Winkler, K. E. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.027 · Cited by 94
A Therapeutic Peptide Vaccine Against PCSK9
Pan, Y., Zhou, Y., Wu, H., Chen, X., Hu, X., Zhang, H., Zhou, Z., Qiu, Z., & Liao, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-13069-w · Cited by 88
O’Connell, E. M., & Lohoff, F. W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00609 · Cited by 93
van Poelgeest, E. P., Hodges, M. R., Moerland, M., Tessier, Y., Levin, A. A., Persson, R., Lindholm, M. W., Dumong Erichsen, K., Ørum, H., Cohen, A. F., et al. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12738 · Cited by 93
Mabuchi, H., Nohara, A., Noguchi, T., Kobayashi, J., Kawashiri, M., Inoue, T., Mori, M., Tada, H., Nakanishi, C., Yagi, K., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.06.005 · Cited by 93
PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes
Hess, C. N., Wang, C. C. L., & Hiatt, W. R. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042716-091351 · Cited by 93
Handelsman, Y., & Lepor, N. E. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008953 · Cited by 86
Adverse Events Associated With PCSK 9 Inhibitors: A Real‐World Experience
Gürgöze, M. T., Muller‐Hansma, A. H. G., Schreuder, M. M., Galema‐Boers, A. M. H., Boersma, E., & Roeters van Lennep, J. E. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1193 · Cited by 92
In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model
Carreras, A., Pane, L. S., Nitsch, R., Madeyski-Bengtson, K., Porritt, M., Akcakaya, P., Taheri-Ghahfarokhi, A., Ericson, E., Bjursell, M., Perez-Alcazar, M., et al. (2019) · BMC Biology · doi:10.1186/s12915-018-0624-2 · Cited by 91
Genetics of Coronary Artery Disease
Musunuru, K., & Kathiresan, S. (2010) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082509-141637 · Cited by 83
Kim, Y., Landstrom, A. P., Shah, S. H., Wu, J. C., & Seidman, C. E. (2024) · Circulation · doi:10.1161/cir.0000000000001296 · Cited by 91
Unravelling the functional significance of PCSK9
Lambert, G. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3281338531 · Cited by 84
Mbikay, M., Sirois, F., Simoes, S., Mayne, J., & Chrétien, M. (2014) · FEBS Open Bio · doi:10.1016/j.fob.2014.08.003 · Cited by 81
Mozas, P., Castillo, S., Tejedor, D., Reyes, G., Alonso, R., Franco, M., Saenz, P., Fuentes, F., Almagro, F., Mata, P., et al. (2004) · Human Mutation · doi:10.1002/humu.9264 · Cited by 84
Lammi, C., Zanoni, C., Aiello, G., Arnoldi, A., & Grazioso, G. (2016) · Scientific Reports · doi:10.1038/srep29931 · Cited by 84
Duarte, Y., Márquez‐Miranda, V., Miossec, M. J., & González-Nilo, F. D. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1554 · Cited by 90
Davignon, J., Dubuc, G., & Seidah, N. G. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0123-6 · Cited by 90
Self-citationAntibody-enabled small-molecule drug discovery
Lawson, A. D. G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3756 · Cited by 90
Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9
Stein, E. A., & Raal, F. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-022613-090402 · Cited by 89
Garg, A., & Simha, V. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0275 · Cited by 89
Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism
Hooper, A. J., van Bockxmeer, F. M., & Burnett, J. R. (2005) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360500295113 · Cited by 89
Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics
Stein, E. A., & Swergold, G. D. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0310-3 · Cited by 89
Knock-out mouse models of proprotein convertases: unique functions or redundancy?
John, W. M. C. (2008) · Frontiers in bioscience · doi:10.2741/3055 · Cited by 89
Ferri, N., & Ruscica, M. (2016) · Endocrine · doi:10.1007/s12020-016-0939-0 · Cited by 89
Baum, S. J., Toth, P. P., Underberg, J. A., Jellinger, P., Ross, J., & Wilemon, K. (2017) · Clinical Cardiology · doi:10.1002/clc.22713 · Cited by 88
“Mutations that cause a reduced affinity of apoB for LDLR also result in decreased LDL clearance and constitute a cause of FH.14 Additional heterogeneity in the hereditary basis for FH became apparent.”
BackgroundInfluentialAlvarez, M. L., Khosroheidari, M., Eddy, E., & Done, S. C. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.08.023 · Cited by 88
Klose, G., Laufs, U., März, W., & Windler, E. E. T. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0523 · Cited by 88
Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation
Xiao, H., Sun, Z., Zhang, H.-B., & Zhang, D. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70883-6 · Cited by 88
Lan, H., Pang, L., Smith, M. M., Levitan, D., Ding, W., Liu, L., Shan, L., Shah, V. V., Laverty, M., Arreaza, G., et al. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22130 · Cited by 82
Herbert, B., Patel, D., Waddington, S. N., Eden, E. R., McAleenan, A., Sun, X.-M., & Soutar, A. K. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.204040 · Cited by 81
Monogenic pediatric dyslipidemias: Classification, genetics and clinical spectrum
Rahalkar, A. R., & Hegele, R. A. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.10.007 · Cited by 88
Ason, B., van der Hoorn, J. W. A., Chan, J., Lee, E., Pieterman, E. J., Nguyen, K. K., Di, M., Shetterly, S., Tang, J., Yeh, W.-C., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m053207 · Cited by 79
Wang, J., Ban, M. R., & Hegele, R. A. (2004) · Journal of Lipid Research · doi:10.1194/jlr.d400030-jlr200 · Cited by 88
Zhu, Y. M., Anderson, T. J., Sikdar, K., Fung, M., McQueen, M. J., Lonn, E. M., & Verma, S. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306172 · Cited by 83
The LXR–Idol Axis Differentially Regulates Plasma LDL Levels in Primates and Mice
Hong, C., Marshall, S. M., McDaniel, A. L., Graham, M., Layne, J. D., Cai, L., Scotti, E., Boyadjian, R., Kim, J., Chamberlain, B. T., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.10.001 · Cited by 87
PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions
Hilvo, M., Simolin, H., Metso, J., Ruuth, M., Öörni, K., Jauhiainen, M., Laaksonen, R., & Baruch, A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.01.004 · Cited by 87
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
Katzmann, J. L., Gouni-Berthold, I., & Laufs, U. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.595819 · Cited by 87
Abdelwahed, K. S., Siddique, A. B., Mohyeldin, M. M., Qusa, M. H., Goda, A. A., Singh, S. S., Ayoub, N. M., King, J. A., Jois, S. D. S., & Sayed, K. A. E. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104847 · Cited by 87
Familial Hypercholesterolemia: The Lipids or the Genes?
Fahed, A. C., & Nemer, G. M. (2011) · Nutrition & Metabolism · doi:10.1186/1743-7075-8-23 · Cited by 87
Methylomic profiling and replication implicates deregulation of PCSK9 in alcohol use disorder
Lohoff, F. W., Sorcher, J. L., Rosen, A. D., Mauro, K. L., Fanelli, R. R., Momenan, R., Hodgkinson, C. A., Vendruscolo, L. F., Koob, G. F., Schwandt, M., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.168 · Cited by 82
PoLA/CFPiP/PCS guidelines for the management of dyslipidaemias for family physicians 2016
Banach, M., Jankowski, P., Jóźwiak, J., Cybulska, B., Windak, A., Guzik, T., Mamcarz, A., Broncel, M., & Tomasik, T. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.64712 · Cited by 86
“The mechanism has been accidentally discovered in patients with very high LDL-C levels and diagnosed autosomal dominant hypercholesterolaemia (a gain-offunction mutation in the PCSK9 protein) and in patients with very low LDL-C levels (< 20 mg/dl) with a loss-of-function mutation following which the non-functional PCS…”
BackgroundKent, S. T., Rosenson, R. S., Avery, C. L., Chen, Y.-D. I., Correa, A., Cummings, S. R., Cupples, L. A., Cushman, M., Evans, D. S., Gudnason, V., et al. (2017) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.116.001632 · Cited by 86
GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation
Poirier, S., Mamarbachi, M., Chen, W.-T., Lee, A. S., & Mayer, G. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.11.006 · Cited by 86
“PCSK9 encodes for a natural inducer of LDLR degradation (Maxwell and Breslow, 2004), for which patients harboring gain-of-function mutations have high levels of circulating LDLc (Abifadel et al., 2003).”
BackgroundTavori, H., Rashid, S., & Fazio, S. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.017 · Cited by 86
“were developed, including: (1) PCSK9-deficient mice, which show lower cholesterol because of over-abundance of LDLR (13); (2) mice over-expressing PCSK9 through adenoviral infection, which show increased cholesterol levels (14, 15); and (3) transgenic models expressing human PCSK9 or some of its gain-of-function mutan…”
InfluentialPersson, L., Gälman, C., Angelin, B., & Rudling, M. (2009) · Endocrinology · doi:10.1210/en.2008-1281 · Cited by 86
Molecular genetics of coronary artery disease
Ozaki, K., & Tanaka, T. (2015) · Journal of Human Genetics · doi:10.1038/jhg.2015.70 · Cited by 86
What lies ahead for the proprotein convertases?
Seidah, N. G. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05883.x · Cited by 75
Self-citationSeidah, N. G. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100130 · Cited by 72
Self-citationCholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia
Elshourbagy, N. A., Meyers, H. V., & Abdel‐Meguid, S. S. (2013) · Medical Principles and Practice · doi:10.1159/000356856 · Cited by 86
Du, F., Hui, Y., Zhang, M., Linton, M. F., Fazio, S., & Fan, D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.273474 · Cited by 80
Paciullo, F., Momi, S., & Gresele, P. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1676863 · Cited by 86
Genetic variants in PCSK9 affect the cholesterol level in Japanese
Shioji, K., Mannami, T., Kokubo, Y., Inamoto, N., Takagi, S., Goto, Y., Nonogi, H., & Iwai, N. (2004) · Journal of Human Genetics · doi:10.1007/s10038-003-0114-3 · Cited by 86
Li, H., Chen, W., Zhou, Y., Abidi, P., Sharpe, O., Robinson, W. H., Kraemer, F. B., & Liu, J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m800375-jlr200 · Cited by 85
Small molecules as inhibitors of PCSK9: Current status and future challenges
Xu, S., Luo, S., Zhu, Z., & Xu, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.011 · Cited by 85
PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction
Sun, H., Krauss, R. M., Chang, J. T., & Teng, B.-B. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m078360 · Cited by 85
Zhang, H., De, T., Zhong, Y., & Perera, M. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1491 · Cited by 85
PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease
Lee, J. S., Mukhopadhyay, P., Matyas, C., Trojnar, E., Paloczi, J., Yang, Y. R., Blank, B. A., Savage, C., Sorokin, A. V., Mehta, N. N., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53603-6 · Cited by 77
Metadata
- Authors
- Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J.-M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., & Boileau, C.
- Affiliations
- Hôpital Necker-Enfants Malades (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Genoscope (FR)
- Montreal Clinical Research Institute (CA)
- Pitié-Salpêtrière Hospital (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Hôpital Claude Huriez (FR)
- Hospices Civils de Lyon (FR)
- ORCID
- Venue
- Nature Genetics
- Published
- 2003-05-05
- Volume
- 34
- Issue
- 2
- Pages
- 154-156
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2040612932
- Semantic Scholar
- 80bf33c74bfe780bcc1968f318b09647e59f0afe
- Cited by
- 2,985
- References
- 6
- Citations by year
- 2026: 88 · 2025: 115 · 2024: 154 · 2023: 175 · 2022: 163 · 2021: 207 · 2020: 182 · 2019: 173 · 2018: 214 · 2017: 232 · 2016: 214 · 2015: 200 · 2014: 162 · 2013: 131 · 2012: 101
- FWCI
- 38.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Institut National de la Santé et de la Recherche Médicale
- Fondation de France
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- PCSK9, autosomal dominant hypercholesterolemia, LDL receptor, apolipoprotein B, LDL cholesterol, genetic mutations, cholesterol homeostasis, subtilases, coronary heart disease risk
- MeSH terms
- Proprotein Convertase 9, Chromosomes, Human, Pair 1, Female, Genes, Dominant, Humans, Hyperlipoproteinemia Type II, Genetic Linkage, Liver, Male, Mutation, Pedigree, Serine Endopeptidases, Amino Acid Substitution, Proprotein Convertases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.